• Nyrada receives HREC approval to initiate first-in-human Phase Ia clinical trial
• Trial will evaluate the safety and tolerability of NYR-BI03 in healthy human volunteers
• Volunteer recruitment to begin shortly, with first dosing anticipated by end of March 2025
• Final Phase Ia trial readout expected in 3QCY2025

Nyrada Inc, a drug discovery and development company focused on innovative Transient Receptor Potential Canonical (TRPC) ion channel blockers, has received approval from the Human Research Ethics Committee (HREC) to initiate its first-in-human Phase Ia clinical trial. The Phase Ia trial will assess the safety, tolerability, and pharmacokinetics of lead drug candidate NYR-BI03 in healthy human volunteers. The trial will be a double-blind, randomised, placebo-controlled, dose escalating study, comprising five (5) cohorts of eight (8) healthy volunteers who will receive intravenous dose over three hours of either NYR-BI03 or placebo. Volunteer recruitment will begin shortly, with the first cohort dosing anticipated to commence by the end of March 2025. Nyrada expects final Phase Ia trial readouts in 3QCY2025 and will provide regular updates throughout the trial. Nyrada's lead drug candidate NYR-BI03 has shown efficacy in both neuroprotection and cardioprotection in preclinical studies.

Nyrada is expecting the results of the joint with WRAIR and UNSW Sydney penetrating TBI study within the coming weeks.